DNDN has never been simple. Thinking CMS was going to do the right thig and it actually doing the right thing are two different scenarios in the battered heads of most DNDN bulls. That's worth 2% at least.
More reasonably, even I didn't think the determination would be this clean. The determination is the label, not the label plus a some other things. If CMS holds very closely to what they published today and issues a NCD, there are patients who will be reimbursed in July who aren't reimbursed today. Not a meaningful amount, but some. The fact I don't have to spend th next three months arguing with some knucklehead about the impact of additional exclusionary criteria is also worth (at least) 2%.
David
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.